search
Back to results

Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy

Primary Purpose

Postoperative Pain

Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Remifentanil infusion
Lidocaine infusion
Magnesium sulphate infusion
Magnesium sulphate and Lidocaine infusion
Sponsored by
Hospital de Base
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Postoperative Pain focused on measuring Intravenous lidocaine, Magnesium sulphate, Mastectomy, Pain

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female patients scheduled for elective surgery performed mastectomy;
  • Physical Status P1 and P2 of the American Society of Anesthesiology (ASA);

Exclusion Criteria:

  • Patients with less than 18 years and above 75 years of age;
  • Patients who are allergic to morphine and / or lidocaine and / or remifentanil and / or magnesium sulphate;
  • Patients with chronic pain;
  • Patients with severe hepatic disease;
  • Patients with severe renal disease;
  • Patients with neurological disorders;
  • Patients included in other clinical currently or within the past three months under general anesthesia studies;
  • Patients who refuse to participate in the study;
  • Any other condition that in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;

Sites / Locations

  • Hospital de Base do Distrito Federal

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Remifentanil group

Lidocaine group

Magnesium group

Magnesium and Lidocaine group

Arm Description

Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.

Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.

Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.

Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate

Outcomes

Primary Outcome Measures

Analgesics consumption in post-operative
Qualification of pain assessed by the amount of analgesics required postoperatively and the time to request them

Secondary Outcome Measures

Pain Scores on the Visual Analog Scale
Quantify pain by Visual Analogue Scale (VAS, ranging from 0 to 10 cm, zero being found when the patient is no pain and ten, with maximum or unbearable pain)
Pain Scores on the Verbal Rating Scale
Verbal Rating Scale (VRS), consisting of a list of phrases (no pain, mild pain, moderate pain, intense pain, maximum pain)
Anesthetic consumption during surgery
amount of intravenous and inhalational anesthetics consumed during surgery
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Intraoperative hemodynamic stability analysis through the incidence of tachycardia, hypertension, bradycardia, hypotension and consumed vasopressors
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Incidence of adverse effects such as time of awakening, nausea, vomiting, pruritus, urinary retention, drowsiness

Full Information

First Posted
November 28, 2014
Last Updated
August 17, 2015
Sponsor
Hospital de Base
search

1. Study Identification

Unique Protocol Identification Number
NCT02309879
Brief Title
Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy
Official Title
Effect of Intravenous Infusion of Lidocaine, Magnesium Sulphate and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized and Double-blind Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital de Base

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to compare the quality of perioperative analgesia of lidocaine, magnesium sulphate and remifentanil in patients undergoing mastectomy
Detailed Description
The opioid analgesics are commonly used in clinical practice for pain management in the perioperative period. However, many side effects are associated with its use, such as respiratory depression, nausea, vomiting, drowsiness, itching, urinary retention, constipation, hyperalgesia and impaired immune function. Therefore, alternative techniques and drugs have been used to replace their use. One is the intravenous infusion of lidocaine, a local anesthetic widely used in anesthetic practice. Another is intravenous infusion of magnesium sulphate, a bivalent salt used as a central nervous system depressor, reducing intracranial hypertension, in the treatment of epilepsy; eclampsia; in chronic alcoholism; in hyaline membranes, such as hyperosmotic diuretic; in malnutrition; hypomagnesaemia; in thrombotic microangiopathy; in sickle cell anemia, uterine tetany and atypical ventricular tachycardia. Studies show that the use alone or combined of lidocaine and magnesium sulphate during surgery significantly decreased postoperative pain. The mechanisms of analgesia this local anesthetic in surgical trauma may be blocking neuronal transmission in the lesion site alleviating neurogenic response, and anti-inflammatory systemic intrinsic activity. Intraoperative lidocaine promotes, besides analgesia, decreased consumption of both inhalational anesthetic and opioids; faster return of bowel movements; decreasing the production of interleukins and reduction of airway reactivity. This anesthetic also has significant anti-inflammatory properties, reduces cytokine release both in vitro and in vivo by inhibiting neutrophil activation. N-methyl-D-aspartate (NMDA) receptors are critically involved in the induction and maintenance of neuronal hyperexcitability after traumatic events, therefore, the use of NMDA antagonists before the incision reduces the excitability of the central nervous system and its result is the reduction of clinical hyperalgesia. Magnesium sulphate is an antagonist of glutamate NMDA receptor, which gives analgesic, anticonvulsant and sedative. It acts as a natural physiological calcium antagonist regulating access to the intracellular space. Shows the effect of muscle relaxation by inhibiting the release of acetylcholine at the neuromuscular junction, thereby hypermagnesaemia decreases sensitivity to acetylcholine of the endplate and the potential amplitude endplate. Besides there are few studies with use of these adjuvants during the perioperative period, the intravenous injection of local anesthetic still arouses oddity among professionals; therefore, the investigators interest in the subject. The patients underwent a prospective, randomized, double blind study, in which the examiners responsible for intra and post-operative will not know which group they were randomly allocated: Lidocaine group (n = 30); Lidocaine and Magnesium group (n = 30); Magnesium group (n = 30) or Remifentanil group (n = 30). Rapid infusion of 0.9% saline 500 ml, in the M and LM group, is added to this solution the loading dose of magnesium sulfate with 50 mg/kg and in group L will only be infused saline 0.9% . Two infusion pumps containing the result of randomization: Lidocaine 3 mg/kg/h and 0.9% saline (L group); magnesium sulphate 15 mg/kg/h and 0.9% saline (M group); lidocaine 3 mg/kg/h and magnesium sulphate 15 mg/kg/hr (LM group); and Remifentanil group (R group). In the clinical record, the following information will be emphasized: Blood pressure and heart rate intraoperative, perioperative side effects, quantify pain by Visual Analogue Scale (VAS) (ranging from 0 to 10 cm, zero being found when the patient is no pain and ten, with maximum or unbearable pain), Verbal Rating Scale (VRS), consisting of a list of phrases (no pain, mild pain, moderate pain, intense pain, maximum pain) and qualification of pain assessed by the amount of analgesics required postoperatively and the time to request them. The results were analyzed statistically with the Statistical Package for Social Sciences (SPSS) version 22 (SPSS Inc., Chicago, IL, EUA) using parametric and nonparametric tests, depending on the nature of the variables studied. Data were tested for normality using the Shapiro-Wilk test. Measures of central tendency (means) and dispersion (standard deviation) were used. The level of significance was set at < 0.05. The following tests were used: Mann-Whitney test for age, duration of anesthesia and surgery, time to first analgesic supplementation, total amount of analgesics, pain intensity; Student t-test for weight and height.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
Intravenous lidocaine, Magnesium sulphate, Mastectomy, Pain

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Remifentanil group
Arm Type
Active Comparator
Arm Description
Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Arm Title
Lidocaine group
Arm Type
Active Comparator
Arm Description
Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Arm Title
Magnesium group
Arm Type
Active Comparator
Arm Description
Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
Arm Title
Magnesium and Lidocaine group
Arm Type
Active Comparator
Arm Description
Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
Intervention Type
Drug
Intervention Name(s)
Remifentanil infusion
Other Intervention Name(s)
Remifentanil hydrochloride
Intervention Description
Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Intervention Type
Drug
Intervention Name(s)
Lidocaine infusion
Other Intervention Name(s)
Lidocaine hydrochloride
Intervention Description
Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Intervention Type
Drug
Intervention Name(s)
Magnesium sulphate infusion
Other Intervention Name(s)
Magnesium sulphate
Intervention Description
Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
Intervention Type
Drug
Intervention Name(s)
Magnesium sulphate and Lidocaine infusion
Other Intervention Name(s)
Magnesium sulphate, Lidocaine hydrochloride
Intervention Description
Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
Primary Outcome Measure Information:
Title
Analgesics consumption in post-operative
Description
Qualification of pain assessed by the amount of analgesics required postoperatively and the time to request them
Time Frame
Within the first 24 hours after surgery
Secondary Outcome Measure Information:
Title
Pain Scores on the Visual Analog Scale
Description
Quantify pain by Visual Analogue Scale (VAS, ranging from 0 to 10 cm, zero being found when the patient is no pain and ten, with maximum or unbearable pain)
Time Frame
Within the first 24 hours after surgery
Title
Pain Scores on the Verbal Rating Scale
Description
Verbal Rating Scale (VRS), consisting of a list of phrases (no pain, mild pain, moderate pain, intense pain, maximum pain)
Time Frame
Within the first 24 hours after surgery
Title
Anesthetic consumption during surgery
Description
amount of intravenous and inhalational anesthetics consumed during surgery
Time Frame
During the surgery
Title
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Description
Intraoperative hemodynamic stability analysis through the incidence of tachycardia, hypertension, bradycardia, hypotension and consumed vasopressors
Time Frame
During the surgery
Title
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Description
Incidence of adverse effects such as time of awakening, nausea, vomiting, pruritus, urinary retention, drowsiness
Time Frame
Within the first 24 hours after surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients scheduled for elective surgery performed mastectomy; Physical Status P1 and P2 of the American Society of Anesthesiology (ASA); Exclusion Criteria: Patients with less than 18 years and above 75 years of age; Patients who are allergic to morphine and / or lidocaine and / or remifentanil and / or magnesium sulphate; Patients with chronic pain; Patients with severe hepatic disease; Patients with severe renal disease; Patients with neurological disorders; Patients included in other clinical currently or within the past three months under general anesthesia studies; Patients who refuse to participate in the study; Any other condition that in the opinion of the investigator, may pose a risk to the patient or interfere with the study objectives;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabricio T Mendonca, MD, TSA
Organizational Affiliation
Hospital de Base do Distrito Federal, Brazil
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Base do Distrito Federal
City
Brasilia
State/Province
DF
ZIP/Postal Code
70680250
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
23669270
Citation
De Oliveira GS Jr, Castro-Alves LJ, Khan JH, McCarthy RJ. Perioperative systemic magnesium to minimize postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2013 Jul;119(1):178-90. doi: 10.1097/ALN.0b013e318297630d.
Results Reference
background
PubMed Identifier
21061107
Citation
Vigneault L, Turgeon AF, Cote D, Lauzier F, Zarychanski R, Moore L, McIntyre LA, Nicole PC, Fergusson DA. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011 Jan;58(1):22-37. doi: 10.1007/s12630-010-9407-0.
Results Reference
background
PubMed Identifier
31977625
Citation
Mendonca FT, Pellizzaro D, Grossi BJ, Calvano LA, de Carvalho LSF, Sposito AC. Synergistic effect of the association between lidocaine and magnesium sulfate on peri-operative pain after mastectomy: A randomised, double-blind trial. Eur J Anaesthesiol. 2020 Mar;37(3):224-234. doi: 10.1097/EJA.0000000000001153.
Results Reference
derived

Learn more about this trial

Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy

We'll reach out to this number within 24 hrs